Phase I clinical trial - Phases précoces tumeurs solides
CPDR001X2103
Phases précoces tumeurs solides
Essai clinique fermé
Public cible
Adulte
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib).
Description de l'essai
The purpose of this study is to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations
Liens utiles